PKBSM6556DJTO

not provided

human beta cell line

EndoC-bH1 cells treated with IL-1b for 24hr from GSE235683

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 50 U/mL Interleukin-1 beta for 86400 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

Homo sapiens

fed1e240-5ca2-4e1e-a7de-170a9858a36a

PKBSM5212UTHG

not provided

human beta cell line

EndoC-bH1 cells treated with TNFa for 24hr from GSE235683

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 1000 U/mL Tumor necrosis factor for 86400 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

Homo sapiens

ed6e91c1-2d7f-4140-ac49-0fe4935d0f1b

PKBSM0734OIDU

not provided

human beta cell line

EndoC-bH1 cells treated with Dexamethasone for 24hr from GSE225901

DMEM containing 5.6 mM glucose, 2% BSA fraction V , 10 mM nicotinamide, 50 μM 2-mercaptoethanol, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite, 100 U/mL penicillin, and 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 2 μM dexamethasone for 86400 seconds, grown in DMEM containing 5.6 mM glucose, 2% BSA fraction V , 10 mM nicotinamide, 50 μM 2-mercaptoethanol, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite, 100 U/mL penicillin, and 100 μg/mL streptomycin

Homo sapiens

e45059c0-9032-471f-99f8-bbe53ca3781f

PKBSM6185LUAS

not provided

human beta cell line

EndoC-bH1 cells infected with CVB4-JVB for 1hr from GSE278756

OPTIβ1 medium

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg CVB4-JVB for 3600 seconds, grown in OPTIβ1 medium

Homo sapiens

87960196-a017-4aa2-b9e4-7cf9a2c202a3

PKBSM8872LHTL

not provided

human beta cell line

EndoC-bH1 cells with empty vector from GSE244273

DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens grown in DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

Homo sapiens

85175954-b866-4ce3-87ef-596ae9ccd503

PKBSM7456TUCI

not provided

human beta cell line

EndoC-bH1 cells treated with IFNa for 8hr from GSE133218

DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 2000 U/mL Interferon alpha-2 for 28800 seconds, grown in DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

Homo sapiens

7971e096-74b4-4217-a65d-6a21ececd080

PKBSM5914TUHA

not provided

human beta cell line

EndoC-bH1 cells with siRNA knockdown of STAT3 from GSE162837

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100 units/mL penicillin, and 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg STAT3 siRNA for 0 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100 units/mL penicillin, and 100 μg/mL streptomycin

Homo sapiens

751d9386-132e-47e2-8c38-43e255021a46

PKBSM4585EHCK

not provided

human beta cell line

EndoC-bH1 cells treated with IFNa for 2hr from GSE133218

DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 2000 U/mL Interferon alpha-2 for 7200 seconds, grown in DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

Homo sapiens

71ee00c3-b7e9-4441-b31e-ce84448a60e3

PKBSM6390TDGG

not provided

human beta cell line

EndoC-bH1 cells with OAS2 expression vector from GSE244273

DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg OAS2 expression vector for 0 seconds, grown in DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

Homo sapiens

71c59334-194f-4856-999b-1e574bedaea1

PKBSM5951LZQK

not provided

human beta cell line

EndoC-bH1 cells treated with IFNg for 24hr from GSE235683

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 1000 U/mL Interferon gamma for 86400 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

Homo sapiens

6f50ce6a-5b53-43c9-a7ac-e992450ac0e8

PKBSM2167ZABS

not provided

human beta cell line

EndoC-bH1 cells untreated from GSE133218

DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens grown in DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

Homo sapiens

6b2ccc0a-45d7-4d27-afce-60e3fd81ddac

PKBSM7264VIZV

not provided

human beta cell line

EndoC-bH1 cells untreated from GSE278756

OPTIβ1 medium

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens grown in OPTIβ1 medium

Homo sapiens

46aef0ae-f2c2-4839-be12-ebac9997f55a

PKBSM1552APTA

not provided

human beta cell line

EndoC-bH1 cells infected with CVB4-E2 for 1hr from GSE278756

OPTIβ1 medium

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg CVB4-E2 for 3600 seconds, grown in OPTIβ1 medium

Homo sapiens

3f7d1066-f1ca-4b29-98a6-82346e740a1e

PKBSM9156OROF

not provided

human beta cell line

EndoC-bH1 cells with OAS1 expression vector from GSE244273

DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg OAS1 expression vector for 0 seconds, grown in DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

Homo sapiens

35f44cf9-8738-488a-a1b4-d123e4596c26

PKBSM5324BMLK

not provided

human beta cell line

EndoC-bH1 cells with OAS3 expression vector from GSE244273

DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg OAS3 expression vector for 0 seconds, grown in DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), and PS (1%)

Homo sapiens

24c5a549-fa7f-4058-a95a-6d28f87f94ce

PKBSM4491SWSY

not provided

human beta cell line

EndoC-bH1 cells untreated from GSE235683

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

Homo sapiens

2414faf3-37c2-4282-9eb5-7a25a8ab4841

PKBSM9253RJLF

not provided

human beta cell line

EndoC-bH1 cells with negative control siRNA from GSE162837

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100 units/mL penicillin, and 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 0 mg/kg Negative control siRNA for 0 seconds, grown in DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100 units/mL penicillin, and 100 μg/mL streptomycin

Homo sapiens

1fa628ff-02ff-4928-bb64-46c352e20f62

PKBSM5907VASA

not provided

human beta cell line

EndoC-bH1 cells treated with IFNa for 24hr from GSE133218

DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens treated with 2000 U/mL Interferon alpha-2 for 86400 seconds, grown in DMEM containing 5.6 mmol/l glucose, 2% BSA fraction V, fatty acid free, 50 μmol/l 2mercaptoethanol, 10 mmol/l nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 units/ml penicillin and 100 μg/ml streptomycin

Homo sapiens

1d216d0f-9bdb-415f-b719-ae276af4cfbc

PKBSM9644SVDK

not provided

human beta cell line

EndoC-bH1 cells untreated from GSE225901

DMEM containing 5.6 mM glucose, 2% BSA fraction V , 10 mM nicotinamide, 50 μM 2-mercaptoethanol, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite, 100 U/mL penicillin, and 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, Homo sapiens grown in DMEM containing 5.6 mM glucose, 2% BSA fraction V , 10 mM nicotinamide, 50 μM 2-mercaptoethanol, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite, 100 U/mL penicillin, and 100 μg/mL streptomycin

Homo sapiens

13ba2662-936c-4b6d-9e9d-664c30343eb7